Sutro Biopharma (STRO) Debt to Equity (2017 - 2023)

Sutro Biopharma has disclosed Debt to Equity across 7 years of filings, most recently posting $0.03 for Q4 2023.

• Debt to Equity for Q4 2023 came in at $0.03, down 63.8% year-over-year; the trailing twelve-month figure through Dec 2023 was $0.03 (down 63.8% YoY), and the FY2023 annual result was $0.03, down 63.8% from the prior year.
• Debt to Equity came in at $0.03 for Q4 2023 at Sutro Biopharma, down from $0.06 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.29 in Q1 2020 to a low of $0.03 in Q4 2023.
• The 5-year median for Debt to Equity is $0.09 (2021), against an average of $0.1.
• Across the five-year window, Debt to Equity surged 199.42% in 2019 and tumbled 72.71% in 2021, its largest moves.
• Sutro Biopharma's Debt to Equity stood at $0.1 in 2019, then retreated by 26.81% to $0.07 in 2020, then soared by 34.51% to $0.1 in 2021, then declined by 24.61% to $0.07 in 2022, then tumbled by 63.8% to $0.03 in 2023.
• The last three Debt to Equity figures came in at $0.03 (Q4 2023), $0.06 (Q3 2023), and $0.07 (Q2 2023), per Business Quant data.